GlobeImmune Priced, Nasdaq: GBIM
Developing therapeutic drugs for pancreatic cancer and hepatitis B and C.
Industry: Health Care
First Day Return: +10.5%
GBIM
Developing therapeutic drugs for pancreatic cancer and hepatitis B and C.
| IPO Data | |
|---|---|
| IPO Date | 07/01/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $15 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Louisville, CO, United States |
| Founded | 1995 |
| Employees at IPO | 25 |
| Website www.globeimmune.com | |
IPO News for GlobeImmune
GlobeImmune (GBIM) Performance
